FDA Aproval
Optionen
| Boardmail an "MisterDurden" |
Wertpapier: Perseon |
http://www.zacks.com/stock/news/39804/BSD+Medical+Settles+Merger+Suit
BSDM | MMSI Print Share Cancer treatment systems maker BSD Medical Corp. (BSDM) has reportedly reached a settlement with shareholders, who filed a lawsuit to block its proposed merger with Utah-based medical product maker Merit MedicalSystems Inc. (MMSI - Snapshot Report).
Merit Medical agreed to acquire Massachusetts-based BSD Medical on May 13, 2010, for roughly $96 million in cash. The offer (valued at $4.38 per BSDM shares) represented a 54% premium over BSD Medical’s closing price of $2.84 on May 12. BSD Medical’s shares spiked 50% following the announcement of the merger.
The transaction, which has been already approved by the Boards of both companies, is subject to closing conditions (including the approval of BSD Medical shareholders and antitrust clearance) and is slated for completion in third-quarter 2010.
However, some BSD Medical shareholders filed a class-action suit in June 2010 in the Delaware Chancery Court for an injunction against the merger. The shareholders accused the directors of BSD Medical for breaching their fiduciary duties in connection with the proposed deal by failing to maximize shareholder value and obtain the best financial and other terms.
Subsequently, the shareholders amended the lawsuit in mid-July 2010 by adding BSD Medical as a defendant. They also indicted that the company’s regulatory filing failed to disclose adequate information about the merger, and instead, provided misleading information.
In a recent filing with the Securities & Exchange Commission (SEC), BSD Medical stated that the settlement, which is subject to court approval, would dismiss all the claims in the class-action suit. The final hearing on the settlement is due on Nov 4, 2010.
BSD Medical focuses on development and marketing of products for embolotherapeutic procedures (minimally invasive surgeries for preventing/reducing blood loss), mainly performed by interventional radiologists. The merger, if consummated, will enable the combined entity to leverage a technology platform, which can be applied to multiple therapeutic areas representing a significant market opportunity.
Besides, it will expand point-of-sale offerings for interventional radiology, targeting the uterine fibroid (tumors of the uterus) and primary liver cancer markets. These are the two major application areas of embolotherapy, which cumulatively represent a global market of over $1 billion.
Merit Medical expects acquisition-related costs (such as transaction fees and restructuring costs) to be dilutive to its earnings in calendar year 2010, but accretive in 2011 and beyond. Besides, it anticipates cost synergies through reduction of sales, marketing and administrative expenses.
http://data.cnbc.com/quotes/BSMD
Es gibt Diskussionen auf yahoo, ob es sich nicht um dieses Unternehmen handelt.
Was die Marktkapitalisierung und den Preis angeht, würde es absolut passen..........
http://www.cnbc.com/id/39076225
Optionen
| Boardmail an "MisterDurden" |
Wertpapier: Perseon |
http://www.boersennotizbuch.de/...n-volumen-zuletzt-hoch-vorsicht.php
hier wurde das letzt Wort noch nicht gesprochen , was den Kurs angeht 
Zumindest kommt heute dank Newsflow mal ein bischen Bewegung rein !
Optionen
| Boardmail an "tom77" |
Wertpapier: Perseon |
bgab hat zwar recht, dass Vorsicht geboten sein sollte, weil "nur 2" Geräte verkauft wurden. Andererseits bedeutet das aber auch, dass aus der Zulassung und den darausfolgenden Meldunge nun Zählbares geworden ist.
Und damit sie 100 Geräte verkaufen können, müssen auch erst einmal die 99 davor an den Mann gebracht werden ;)
Ic hoffe, und das können nur die kommenden Tage zeigen, ob damit eine positive Entwicklung angestossen wurde. Erfreulich wäre es ja.
Optionen
| Boardmail an "MisterDurden" |
Wertpapier: Perseon |
Stellt sich aber dennoch die Frage, warum wir heute zweistellig steigen. Gibts News?
Optionen
| Boardmail an "MisterDurden" |
Wertpapier: Perseon |
